Apollo Therapeutics

Today we’re celebrating Apollo Therapeutics’ five-year anniversary.   Since becoming an independent biopharma company in 2021, Apollo has grown rapidly building a strong, experienced team across the UK and US and establishing real momentum as an organisation.   Over that time, we’ve advanced our pipeline, deepened our partnerships, and continued to translate cutting-edge academic research into new medicines. What started as a small team with an ambitious, differentiated model has evolved into a business with a clear track record of delivery.   This milestone reflects the people behind Apollo. Our progress is grounded in collaboration, high standards, and a shared commitment to doing things differently.   It’s a moment to reflect - but even more, to look ahead. We’re proud of how far we’ve come and excited about what comes next as we continue to bring breakthrough science closer to patients.   #biopharma #science #anniversary #ApolloTherapeutics

Apollo Therapeutics will be attending the Revolutionizing Atopic Dermatitis (RAD) Conference, taking place June 17–19 in Nashville, TN.    We look forward to engaging with colleagues across the dermatology and broader life sciences community.    #ApolloTherapeutics #RAD2026 #AtopicDermatitis #Dermatology  Michael Weinreich

Timothy P. Walbert has been appointed Chairman of Apollo Therapeutics’ board.    With more than 30 years of biopharmaceutical leadership, including founding and leading Horizon Therapeutics through to its ~$28.3bn acquisition by Amgen, Tim brings deep experience in building and scaling successful companies and commercializing new medicines.    As Dr Richard Mason, CEO, commented:  “Tim has an exceptional track record. His experience translating compelling science into important medicines for patients and successfully commercializing them is exactly the perspective Apollo needs for its next phase of growth as we execute our strategy and vision, including ultimately the commercialization of our products.    We look forward to working with Tim as we continue to turn breakthrough science into differentiated medicines for patients.”    Read more: https://lnkd.in/efw38BsX

Apollo Therapeutics will be attending the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden.  Apollo will have a poster on display at the conference on Friday, 12 June, led by Nadine Clemo, VP, Global Program Lead. We look forward to engaging with colleagues across the hematology and life sciences community.  #ApolloTherapeutics #EHA2026 #Hematology  Martin Michel

Apollo Therapeutics will be attending the upcoming Imperial Collider, hosted by Imperial College London: Health – Innovations for Partners, People & Populations.    CEO, Richard Mason, will be speaking on the panel “Biomedical sector landscape and key trends,” exploring the current biopharma landscape, including key trends, challenges, and opportunities shaping innovation and investment.    VP, Head of Research Partnerships, Kay Penicud, will be speaking on the panel “Partnering that works: identifying science and building collaboration,” focusing on how successful partnerships are built and how high-potential science is translated into real-world impact.    At Apollo Therapeutics we match our world-class industrial drug discovery and drug development capabilities with basic medical breakthroughs made at our top university partners to create important new medicines.      We look forward to engaging with peers and collaborators at the event.    #ApolloTherapeutics #ImperialCollider #Partnerships #Collaboration 

Delighted that Rachel Gurrell of Apollo Therapeutics, will be speaking at the Genetics‑inspired Therapeutics for Pulmonary Hypertension: PVRI Symposium next week on June 2. Rachel will share perspectives on targeting ZIP12 inhibition for the treatment of pulmonary hypertension, contributing to the wider scientific discussion on how genetic insights can help shape the future of treatment development across the field. #ApolloTherapeutics #PulmonaryHypertension #Genetics #DrugDiscovery #TherapeuticInnovation #LifeSciences #PVRI

Strong engagement for Apollo Therapeutics at the Society for Investigative Dermatology (SID) Annual Meeting in Chicago last week. Richard Brown, our Global Program Leader for camoteskimab, presented data from our recent Phase 2a clinical trial in atopic dermatitis.  We look forward to sharing further clinical data from this trial at upcoming conferences later this year. In parallel, recruitment for our global Phase 2b dose-ranging clinical trial is now underway, marking a key milestone as we continue to advance camoteskimab through development for the treatment of patients with moderate to severe atopic dermatitis. #ApolloTherapeutics #SIDChicago2026 #Dermatology #camoteskimab 

Apollo Therapeutics will be attending the American Thoracic Society (ATS) 2026 International Conference, taking place May 15–20 in Orlando, Florida.      The team looks forward to engaging with colleagues across the respiratory and broader life sciences community. We look forward to seeing you there.      #ApolloTherapeutics #ATS2026 #Pulmonary #Respiratory  Daniel Wilkinson Rachel Gurrell Malcolm Begg Ph.D. FBPhS

Apollo Therapeutics will be attending the Society for Investigative Dermatology (SID) Annual Meeting, taking place May 13 - 16 in Chicago.   On Thursday 14 May, our Chief Medical Officer, Sanjay Aggarwal, will present new data from the phase 2a study of camoteskimab, our anti‑IL‑18 monoclonal antibody. The presentation will highlight emerging insights from this program and its potential for the treatment of atopic dermatitis.   We look forward to engaging with colleagues across the dermatology community at SID. #ApolloTherapeutics #SIDChicago2026 #Dermatology Arjun Krishnan Daniel Wilkinson Richard Brown Michael Weinreich

Delighted that Rachel Gurrell of Apollo Therapeutics, will be speaking at the Genetics‑inspired Therapeutics for Pulmonary Hypertension: PVRI Symposium this June. Rachel will share perspectives on targeting ZIP12 inhibition for the treatment of pulmonary hypertension, contributing to the wider scientific discussion on how genetic insights can help shape the future of treatment development across the field. #Apollotherapeutics #PulmonaryHypertension #Genetics #DrugDiscovery #TherapeuticInnovation #LifeSciences